Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy
LOS ANGELES–(BUSINESS WIRE)–Pelage Pharmaceuticals, a clinical-stage regenerative medicine company, today announced positive results from its Phase 2a clinical trial of PP405 — a topical therapy for androgenetic alopecia advancing through the FDA clinical development pathway. PP405 is designed to reactivate dormant hair follicle stem cells, offering a potential first-in-class approach for both men and women experiencing hair loss.
The Phase 2a randomized controlled trial enrolled a total of 78 men and women with androgenetic alopecia, representing a diverse range of skin phototypes and hair textures. The subjects applied PP405 or a placebo on their scalp once daily for 4 weeks and were followed out to 12 weeks. The study met its primary safety endpoint and secondary pharmacokinetic endpoint: the drug was well tolerated with no systemic absorption of PP405 detected in the blood, underscoring a robust safety profile. Exploratory endpoints assessed early signs of new hair growth.
